Potent Inhibitory Effect of Sr 49059, An Orally Active Non-Peptide Vasopressin via Receptor Antagonist, on Human Arterial Coronary Bypass Graft

1995 ◽  
Vol 89 (5) ◽  
pp. 481-485 ◽  
Author(s):  
James J. Liu ◽  
Joan R. Chen ◽  
Brian B. Buxton ◽  
Colin I. Johnston ◽  
Louise M. Burrell
Keyword(s):  
Receptor Antagonist ◽  
Bypass Graft ◽  
Coronary Bypass ◽  
Inhibitory Effect ◽  
V1a Receptor ◽  
Mammary Arteries ◽  
Coronary Bypass Graft ◽  
Internal Mammary ◽  
Vasopressin V1a Receptor

1. The effect of vasopressin receptor antagonists varies between analogues (peptide, non-peptide) and across species. In this study the effect of the novel non-peptide vasopressin V1a receptor antagonist SR 49059 on human internal mammary arteries was investigated. 2. SR 49059 produced a potent, concentration-dependent, inhibitory effect on vasopressin-induced contraction of human coronary bypass graft internal mammary arteries. Both SR 49059 (1 μmol/l) and a peptide selective V1a antagonist {[d(CH2)5sarcosine7]arginine vasopressin} (1 μmol/l) abolished vasopressin-induced contraction. The non-peptide V1a receptor antagonist OPC-21268 (1 μmol/l) had no effect on vasopressin-induced contraction. 3. The effect of SR 49059 was specific to vascular vasopressin receptors as noradrenaline-induced contraction was not influenced by SR 49059. 4. The results of this study in vitro indicate that the non-peptide SR 49059 is a potent, specific vasopressin V1a receptor antagonist in the human internal mammary artery and suggest that it may be a useful tool for studying the pathophysiological role of vasopressin in man.

An Improved Technique for the Internal Mammary Artery Coronary Bypass Graft Procedure

1988 ◽  
Vol 3 (4) ◽  
pp. 467-473 ◽  
Author(s):  
VINCENT A. GAUDIANI ◽  
WALLY S. BUCH ◽  
ALBERT K. CHIN ◽  
LAURIE J. AYRES ◽  
THOMAS J. FOGARTY
Keyword(s):  
Internal Mammary Artery ◽  
Bypass Graft ◽  
Coronary Bypass ◽  
Coronary Bypass Graft ◽  
Internal Mammary ◽  
Improved Technique

Vascular Responses to Vasopressin Antagonists in Man and Rat

1994 ◽  
Vol 87 (4) ◽  
pp. 389-395 ◽  
Author(s):  
Louise M. Burrell ◽  
Paddy A. Phillips ◽  
K. A. Rolls ◽  
B. F. Buxton ◽  
C. I. Johnston ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Arginine Vasopressin ◽  
Resistance Arteries ◽  
Antagonist Activity ◽  
Receptor System ◽  
Mammary Arteries ◽  
Internal Mammary ◽  
V2 Receptor ◽  
V2 Receptor Antagonist

1. The effects of the non-peptide arginine vasopressin V1 receptor antagonist (OPC-21268) and the non-peptide V2 receptor antagonist (OPC-31260) on vasopressin-induced contraction of human internal mammary arteries and rat mesenteric resistance arteries were investigated. 2. In human internal mammary arteries, the non-peptide V1 receptor antagonist, OPC-21268, failed to antagonize vasopressin-induced contraction at low concentrations and potentiated the contraction at higher concentrations (300 nmol/l, P < 0.05). A peptide selective V1 receptor antagonist {[d(CH2)5, sarcosine7]arginine vasopressin} potently inhibited the vasopressin-induced contraction, indicating the presence of functionally constrictor V1 receptors in human internal mammary arteries. Both peptide (desGly-NH29[d(CH2)5, D-Ile2, Ile4]arginine vasopressin) and non-peptide ‘selective’ V2 receptor antagonists (OPC-31260, 3 μmol/l) significantly antagonized vasopressin-induced contraction (P < 0.01), indicating partial V1 receptor antagonist activity. 3. The vasopressin-induced contraction in human internal mammary arteries was reversed by high concentrations of the non-peptide V2 receptor antagonist, OPC-31260, but not by the non-peptide V1 receptor antagonist, OPC-21268. 5. In rat mesenteric resistance arteries, both OPC-21268 (10 nmol/l) and OPC-31260 (1 μmol/l) antagonized vasopressin-induced contraction (P < 0.01). 6. The results of this study in vitro indicate that in human internal mammary arteries, the non-peptide OPC-21268 is a partial V1 receptor agonist with no V1 receptor antagonist activity, whereas the non-peptide OPC-31260 acts as a V1 receptor antagonist. Both OPC-21268 and OPC-31260 have V1 receptor antagonistic activity in vitro in the rat mesenteric resistance arteries. 7. These findings illustrate the complexity of the vasopressin receptor system and highlight the variability in results with peptide or non-peptide vasopressin analogues, between studies in vivo or in vitro, between species and across vascular beds.

Development of Vascular Substitutes

1998 ◽  
Vol 550 ◽  
Author(s):  
Robert M. Nerem
Keyword(s):  
Bypass Graft ◽  
Small Diameter ◽  
Coronary Bypass ◽  
Georgia Tech ◽  
The Past ◽  
Coronary Bypass Graft ◽  
Term Objective ◽  
Stimulation Of

AbstractA long-term objective of many involved in blood vessel research is the development of a small diameter vascular substitute which can be used in coronary bypass graft surgery. If these efforts are to be successful, there are critical functional characteristics which must be achieved. In recent years many of those interested have turned their attention to tissue engineering, and over the past decade some progress has been reported. The results of some of these efforts are briefly reviewed here. Included is the strategy of the Georgia Tech team and recent results which demonstrate that in vitro mechanical stimulation of smooth muscle cell-seeded tubular collagen constructs induces a remodeling with the result that the associated material properties are considerably enhanced.

Sign in / Sign up

Export Citation Format

Share Document